How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/im-haloperidol-plus-lorazepam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IM haloperidol plus lorazepam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IM haloperidol plus lorazepam (IM haloperidol plus lorazepam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipsychotic + benzodiazepine combination. Area: Psychiatry / Behavioral Health.

phase 3 Antipsychotic + benzodiazepine combination Dopamine D2 receptor (haloperidol); GABA-A receptor (lorazepam) Psychiatry / Behavioral Health Small molecule Live · refreshed every 30 min

Target snapshot

IM haloperidol plus lorazepam (IM haloperidol plus lorazepam) — National Taiwan University Hospital. IM haloperidol blocks dopamine receptors to reduce psychotic symptoms, while lorazepam enhances GABA signaling to provide sedation and anxiolysis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IM haloperidol plus lorazepam TARGET	IM haloperidol plus lorazepam	National Taiwan University Hospital	phase 3	Antipsychotic + benzodiazepine combination	Dopamine D2 receptor (haloperidol); GABA-A receptor (lorazepam)
Haloperidol + lorazepam	Haloperidol + lorazepam	University of Arkansas	marketed	Antipsychotic + benzodiazepine combination	Dopamine D2 receptor (haloperidol); GABA-A receptor (lorazepam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipsychotic + benzodiazepine combination class)

National Taiwan University Hospital · 1 drug in this class
University of Arkansas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM haloperidol plus lorazepam — Competitive Intelligence Brief. https://druglandscape.com/ci/im-haloperidol-plus-lorazepam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing